サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551519

骨がん治療の世界市場

Bone Cancer Treatment

出版日
ページ情報
英文 367 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
骨がん治療の世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 367 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

骨がん治療の世界市場は2030年までに15億米ドルに達する見込み

2023年に12億米ドルと推定される骨がん治療の世界市場は、2030年には15億米ドルに達し、分析期間2023-2030年のCAGRは3.0%で成長すると予測されます。本レポートで分析したセグメントの1つである骨肉腫治療は、CAGR 3.4%を記録し、分析期間終了時には8億8,040万米ドルに達すると予測されます。軟骨肉腫治療分野の成長率は、分析期間中CAGR 2.7%と推定されます。

米国市場は3億2,620万米ドルと推定、中国はCAGR 5.8％で成長予測

米国の骨がん治療市場は、2023年に3億2,620万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 5.8%で推移し、2030年には2億9,930万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9%と2.2%と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界の骨がん治療市場- 主要動向と促進要因のまとめ

骨がん治療はどのように進歩してきたか？

骨がん治療は、初歩的なアプローチから高度に専門化された標的療法へと、長年にわたり目覚ましい進歩を遂げてきました。伝統的に、骨がんの治療は外科的介入に大きく依存しており、腫瘍を切除するために切断や四肢温存手術を伴うことが多かった。外科手術が治療の要であることに変わりはないが、化学療法と放射線療法の導入により、状況は劇的に変化しました。急速に分裂する細胞を標的とする化学療法は、手術の標準的な補助療法となり、切除前に腫瘍を縮小させ、術後に残存するがん細胞を除去するのに役立っています。一方、放射線療法は、強度変調放射線療法（IMRT）や陽子線治療など、周囲の健康な組織を温存しながらがん細胞を標的として破壊できる、より精密な技術の出現によって発展してきました。これらの開発により、生存率が向上しただけでなく、患者の生活の質も大幅に向上し、思い切った外科手術の必要性が減り、長期的な副作用も最小限に抑えられています。

骨がん治療の新たな動向とは？

骨がん治療の新たな動向は、より個別化された、より低侵襲な治療オプションの探求によってもたらされています。最も重要な動向の一つは、がんの成長を促進する特定の遺伝子変異やタンパク質に焦点を当てた標的療法の台頭です。チロシンキナーゼ阻害剤やモノクローナル抗体などの薬剤がこの動向の最前線にあり、従来の化学療法に代わる、より効果的で毒性の少ない治療法を提供しています。もうひとつの重要な動向は、免疫療法の発展です。これは、身体の免疫システムを利用してがんと闘うものです。チェックポイント阻害剤とCAR T細胞療法がこの分野をリードしており、最も侵攻性の高い骨がんの治療にも有望視されています。さらに、PETスキャンやMRIなどの画像診断の進歩により、腫瘍の検出とモニタリングの精度が向上し、早期介入やより正確な治療計画が可能となっています。画像診断と治療計画における人工知能（AI）の統合も普及しつつあり、腫瘍医に治療結果をより正確に予測し、治療を個別化するためのツールを提供しています。さらに、ラジオ波焼灼術やクライオアブレーションなどの低侵襲手術技術の動向は、特に従来の手術が実行不可能な患者に新たな選択肢を提供しています。

医療科学の革新はどのように骨がん治療を変革しているのか？

医療科学の革新は、より効果的で侵襲が少なく、個々の患者に合わせた新しい治療法を導入することにより、骨がん治療を変革しています。最も画期的な技術革新のひとつは、遺伝子治療の開発です。遺伝子治療とは、がん細胞内の遺伝物質を変化させ、その増殖を止めたり、他の治療法に対する感受性を高めたりするものです。臨床試験では現在、さまざまな遺伝子治療アプローチが検討されており、骨がん患者の予後改善に早くから有望視されているものもあります。ナノテクノロジーも画期的な研究分野であり、ナノ粒子を用いて腫瘍部位に直接薬剤を送達することで、健康な組織へのダメージを最小限に抑え、化学療法の効果を高めています。カスタムメイドの骨インプラントや補綴物の作成に3Dプリンティング技術を使用することで、術後の回復にも革命が起きており、より精密な再建やより優れた機能的転帰が可能となっています。さらに、幹細胞治療の進歩は、がんやその治療によって引き起こされた骨の損傷を修復する可能性が検討されており、回復と生活の質の向上への希望をもたらしています。これらの技術革新は、患者が利用できる治療の選択肢を広げるだけでなく、骨がんがより効果的に、より少ない副作用で管理される未来への舞台を整えつつあります。

骨がん治療市場の成長を促進する要因は？

骨がん治療市場の成長は、先進的で効果的な治療法に対する需要の増加を強調するいくつかの要因によって牽引されています。第一に、特に高齢化社会における骨がんの発生率の上昇が大きな推進力となっています。平均寿命が延びるにつれて、様々なタイプの骨がんを含む高齢者に多いがんの有病率も増加します。第二に、医療技術と製薬研究の継続的な進歩により、新規化学療法剤から最先端の免疫療法や標的療法まで、利用可能な治療法が拡大しています。このような技術革新は、患者の予後を改善し、新たな治療法の普及につながっています。もう一つの重要な要因は、個々の患者の遺伝子プロファイルに合わせて治療を行う個別化医療が重視されるようになってきたことです。このアプローチは、サブタイプによって様々な治療への反応が異なる骨がんに特に関連しています。さらに、新興市場におけるヘルスケア・インフラの拡大や先進医療へのアクセスも、より多くの患者が最先端の治療を受けられるようになり、市場の成長に寄与しています。臨床試験の利用可能性が高まり、がん研究における世界の共同研究が活発化していることも市場拡大に拍車をかけており、以前は利用できなかった実験的治療法を患者が利用できるようになっています。最後に、骨がんに対する意識の高まりと早期発見は、効果的な治療と生存率の向上に不可欠な早期介入につながっており、高度な治療オプションの需要を促進しています。

調査対象企業の例（注目の34社）

  • Atlanthera
  • Bayer AG
  • Cadila Pharmaceuticals
  • CancerVax
  • Cellectar Biosciences, Inc.
  • Cipla, Inc.
  • Debiopharm Group
  • GlaxoSmithKline plc.
  • Healthcare Global Enterprises Ltd.
  • Isofol Medical AB
  • Janssen Global Services LLC
  • Johnson and Johnson
  • Max Healthcare
  • Novartis International AG
  • Pfizer Inc.
  • Zentalis Pharmaceuticals

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26714

Global Bone Cancer Treatment Market to Reach US$1.5 Billion by 2030

The global market for Bone Cancer Treatment estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Osteosarcoma Treatment, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$880.4 Million by the end of the analysis period. Growth in the Chondrosarcoma Treatment segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$326.2 Million While China is Forecast to Grow at 5.8% CAGR

The Bone Cancer Treatment market in the U.S. is estimated at US$326.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$299.3 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Bone Cancer Treatment Market - Key Trends and Drivers Summarized

How Has Bone Cancer Treatment Advanced Over the Years?

Bone cancer treatment has seen remarkable advancements over the years, moving from rudimentary approaches to highly specialized and targeted therapies. Traditionally, treatment for bone cancer relied heavily on surgical intervention, often involving amputation or limb-sparing surgeries to remove the tumor. While surgery remains a cornerstone of treatment, the landscape has shifted dramatically with the introduction of chemotherapy and radiation therapy. Chemotherapy, which targets rapidly dividing cells, became a standard adjunct to surgery, helping to shrink tumors before removal and to eliminate residual cancer cells post-surgery. Radiation therapy, on the other hand, has evolved with the advent of more precise techniques, such as intensity-modulated radiation therapy (IMRT) and proton therapy, which allow for the targeted destruction of cancer cells while sparing surrounding healthy tissue. These developments have not only improved survival rates but have also significantly enhanced the quality of life for patients, reducing the need for drastic surgical procedures and minimizing long-term side effects.

What Are the Emerging Trends in Bone Cancer Treatment?

Emerging trends in bone cancer treatment are driven by the quest for more personalized and less invasive therapeutic options. One of the most significant trends is the rise of targeted therapies, which focus on specific genetic mutations or proteins that drive cancer growth. Drugs like tyrosine kinase inhibitors and monoclonal antibodies are at the forefront of this trend, offering more effective and less toxic alternatives to traditional chemotherapy. Another critical trend is the development of immunotherapy, which harnesses the body’s immune system to fight cancer. Checkpoint inhibitors and CAR T-cell therapy are leading the charge in this area, showing promise in treating even the most aggressive forms of bone cancer. Additionally, advances in diagnostic imaging, such as PET scans and MRI, are improving the accuracy of tumor detection and monitoring, allowing for earlier intervention and more precise treatment planning. The integration of artificial intelligence (AI) in imaging and treatment planning is also gaining traction, providing oncologists with tools to better predict treatment outcomes and personalize therapy. Moreover, the trend towards minimally invasive surgical techniques, such as radiofrequency ablation and cryoablation, is offering new options for patients, particularly those for whom traditional surgery is not viable.

How Are Innovations in Medical Science Transforming Bone Cancer Treatment?

Innovations in medical science are transforming bone cancer treatment by introducing new modalities that are more effective, less invasive, and tailored to the individual patient. One of the most transformative innovations is the development of gene therapy, which involves altering the genetic material within cancer cells to stop their growth or to make them more susceptible to other treatments. Clinical trials are currently exploring various gene therapy approaches, with some showing early promise in improving outcomes for patients with bone cancer. Nanotechnology is another groundbreaking area of research, where nanoparticles are used to deliver drugs directly to the tumor site, minimizing damage to healthy tissue and enhancing the efficacy of chemotherapy. The use of 3D printing technology in the creation of custom bone implants and prosthetics is also revolutionizing post-surgical recovery, allowing for more precise reconstructions and better functional outcomes. Additionally, advances in stem cell therapy are being explored for their potential to repair bone damage caused by cancer or its treatment, offering hope for improved recovery and quality of life. These innovations are not only expanding the treatment options available to patients but are also setting the stage for a future where bone cancer can be managed more effectively and with fewer side effects.

What Factors Are Driving the Growth in the Bone Cancer Treatment Market?

The growth in the bone cancer treatment market is driven by several factors that highlight the increasing demand for advanced and effective therapies. Firstly, the rising incidence of bone cancer, particularly among the aging population, is a significant driver. As life expectancy increases, so does the prevalence of cancers that are more common in older adults, including various types of bone cancer. Secondly, the ongoing advancements in medical technology and pharmaceutical research are expanding the arsenal of available treatments, from novel chemotherapy agents to cutting-edge immunotherapies and targeted therapies. These innovations are improving patient outcomes, leading to greater adoption of new treatment modalities. Another critical factor is the growing emphasis on personalized medicine, where treatments are tailored to the genetic profile of the individual patient. This approach is particularly relevant in bone cancer, where different subtypes respond differently to various treatments. Additionally, the expansion of healthcare infrastructure and access to advanced medical care in emerging markets is contributing to market growth, as more patients gain access to state-of-the-art treatments. The increasing availability of clinical trials and the rise of global collaboration in cancer research are also fueling market expansion, offering patients access to experimental therapies that were previously unavailable. Lastly, the heightened awareness and early detection of bone cancer are leading to earlier intervention, which is crucial for effective treatment and improving survival rates, thereby driving the demand for advanced treatment options.

Select Competitors (Total 34 Featured) -

  • Atlanthera
  • Bayer AG
  • Cadila Pharmaceuticals
  • CancerVax
  • Cellectar Biosciences, Inc.
  • Cipla, Inc.
  • Debiopharm Group
  • GlaxoSmithKline plc.
  • Healthcare Global Enterprises Ltd.
  • Isofol Medical AB
  • Janssen Global Services LLC
  • Johnson and Johnson
  • Max Healthcare
  • Novartis International AG
  • Pfizer Inc.
  • Zentalis Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Bone Cancer Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Targeted Therapies Propel Growth in Bone Cancer Treatment Market
    • Rising Incidence of Osteosarcoma Expands Addressable Market Opportunity for Specialized Treatments
    • Emergence of Immunotherapy Strengthens Business Case for Innovative Bone Cancer Treatments
    • Advent of Novel Chemotherapy Agents Drive Adoption in Bone Cancer Care
    • Focus on Precision Medicine Generates Demand for Personalized Bone Cancer Treatment Solutions
    • Integration of Genomic Testing in Oncology Throws the Spotlight on Tailored Bone Cancer Therapies
    • Increasing Use of Combination Therapies Spurs Growth in Multi-Modal Bone Cancer Treatment Approaches
    • Challenges in Early Diagnosis of Bone Cancer Present Opportunities for Advanced Diagnostic Tools
    • Rising Healthcare Expenditure and Access to Advanced Oncology Care Sustain Growth in Bone Cancer Treatment Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bone Cancer Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bone Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Osteosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Osteosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Osteosarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chondrosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chondrosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chondrosarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ewing Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ewing Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Ewing Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Immunotherapy & Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Immunotherapy & Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Immunotherapy & Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Bone Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Bone Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: India 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Bone Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Bone Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION